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ABSTRACT 
 
Rationale: The ETS transcription factor (TF) ERG is essential for endothelial homeostasis, driving 
expression of lineage genes and repressing pro-inflammatory genes. Loss of ERG expression is associated 
with diseases including atherosclerosis. ERG’s homeostatic function is lineage-specific, since aberrant 
ERG expression in cancer is oncogenic. The molecular basis for ERG lineage-specific activity is unknown. 
Transcriptional regulation of lineage specificity is linked to enhancer clusters (super-enhancers).  
 
Objective: To investigate whether ERG regulates endothelial-specific gene expression via super-enhancers. 
 
Methods and Results: Chromatin immunoprecipitation with high-throughput sequencing (ChIP-seq) in 
human umbilical vein endothelial cells (HUVEC) showed that ERG binds 93% of super-enhancers ranked 
according to H3K27ac, a mark of active chromatin. These were associated with endothelial genes such as 
DLL4, CLDN5, VWF and CDH5. Comparison between HUVEC and prostate cancer TMPRSS2:ERG 
fusion-positive VCaP cells revealed distinctive lineage-specific transcriptome and super-enhancer profiles. 
At a subset of endothelial super-enhancers (including DLL4 and CLDN5), loss of ERG results in significant 
reduction in gene expression which correlates with decreased enrichment of H3K27ac and Mediator subunit 
MED1, and reduced recruitment of acetyltransferase p300. At these super-enhancers, co-occupancy of 
GATA2 and AP-1 is significantly lower compared to super-enhancers that remained constant following 
ERG inhibition. These data suggest distinct mechanisms of super-enhancer regulation in EC and highlight 
the unique role of ERG in controlling a core subset of super-enhancers. Most disease-associated single 
nucleotide polymorphisms (SNPs) from genome-wide association studies (GWAS) lie within noncoding 
regions and perturb TF recognition sequences in relevant cell types. Analysis of GWAS data shows 
significant enrichment of risk variants for CVD and other diseases, at ERG endothelial enhancers and super-
enhancers.  
 
Conclusions: The TF ERG promotes endothelial homeostasis via regulation of lineage-specific enhancers 
and super-enhancers. Enrichment of CVD-associated SNPs at ERG super-enhancers suggests that ERG-
dependent transcription modulates disease risk.  
 
Keywords:  
Epigenetics, gene expression and regulation, endothelium, endothelial cell, transcription factors, super-
enhancers.  
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Nonstandard Abbreviations and Acronyms: 
 
BRD4  Bromodomain-containing protein 4 
CAD  Coronary artery disease 
ChIP-seq Chromatin immunoprecipitation with deep sequencing 
CVD  Cardiovascular disease 
EC  Endothelial cell 
ERG  Ets-Related Gene 
ETS  E-26 transformation specific transcription factor 
ENCODE Encyclopedia of DNA Elements 
GO  Gene ontology 
GSEA  Gene set enrichment analysis 
GWAS  Genome-wide association study 
HAEC  Human aortic endothelial cell 
HUVEC Human umbilical vein endothelial cell 
LDTF  Lineage determining transcription factor 
MED1  Mediator complex subunit 1 
SE  Super-enhancers 
SNP  Single nucleotide polymorphism 
TF   Transcription factor 
TMPRSS2 Transmembrane protease, serine 2 
TSS  Transcription start site 
VCaP  Human prostate epithelial cancer cell line 
 
 
 
INTRODUCTION  
 
Maintenance of endothelial homeostasis is essential for vascular health. Disruption of endothelial 
homeostasis, as observed in atherosclerosis and in chronic inflammatory diseases, leads to profound 
changes in the phenotype of endothelial cells (EC) with upregulation of pro-inflammatory pathways and 
loss of anti-inflammatory pathways. Loss of endothelial lineage identity is associated with endothelial-to-
mesenchymal transition (EndMT), a process implicated in multiple diseases1. The transcriptional 
mechanisms regulating EC lineage identity and maintenance of endothelial homeostasis are also areas of 
immense interest for vascular regenerative therapies, but remain poorly understood.  
 
The ETS transcription factor ERG is a critical regulator of endothelial homeostasis (reviewed in 2). 
In the endothelium, ERG expression appears around developmental day E8.5 and is maintained into 
adulthood3. ERG is required for endothelial lineage specification4, vascular development and angiogenesis5; 
endothelial-specific deletion of Erg in mouse results in embryonic lethality due to vascular defects6, 7. ERG 
drives expression of lineage-specific genes such as VE-cadherin (CDH5), DLL4, claudin-5 (CLDN5) and 
von Willebrand factor (VWF) and controls processes including survival, permeability and cytoskeletal 
dynamics (reviewed in 2). Molecular pathways through which ERG promotes vascular stability and 
angiogenesis include Wnt/β-catenin signaling6 and angiopoietin-1-dependent Notch signaling8. ERG 
maintains vascular homeostasis also by repressing expression of pro-inflammatory genes such as ICAM1 
and IL8 9, 10 and by protecting from EndMT11. In line with its homeostatic role, ERG’s expression is lost in 
vascular diseases such as the activated endothelium overlying human atherosclerotic plaques10. 
However, aberrant expression of ERG in non-EC can be detrimental. ERG overexpression as the result of 
chromosomal translocations in prostate cancer correlates with malignancy and invasiveness, poor prognosis 
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and shorter survival times12. In these circumstances ERG acts as an oncogene. Since the first report of gene 
fusions between ERG and the regulatory region of the androgen-dependent TMPRSS2 gene13, the molecular 
mechanisms through which ERG aberrant expression is oncogenic have been investigated in detail 
(reviewed in 14). The striking difference between the homeostatic versus oncogenic roles of ERG has 
important implications for the possible therapeutic potential of this pathway in pathologies associated with 
cardiovascular disease (CVD).  
 
The mechanistic basis for the difference in ERG’s lineage specific activity may lie in the chromatin 
landscape. Genetic regulatory elements, called enhancers, play a key role in mediating the transcriptional 
regulation of lineage-specific gene expression15. Enhancer activation by transcription factors (TF) is 
cooperative and hierarchical15-17. Members of the ETS, AP-1 and GATA families have been shown to 
functionally interact at enhancers associated with lineage-specific genes16. Recently, clusters of enhancer 
elements variably termed super-enhancers, stretch enhancers or enhancer clusters, have been described in 
numerous cell types, including EC18-21. These regulatory elements are associated with an extremely high 
abundance of TFs, H3K27ac-modified nucleosomes and Mediator complex and drive cell type-specific 
gene expression18, 19. 
 
Furthermore, super-enhancers are enriched in single nucleotide polymorphisms (SNPs) associated 
with specific diseases, in a cell type-specific manner18. The majority of SNPs identified by genome-wide 
association studies (GWAS) associated with human disease traits are localized to non-coding regions of the 
genome22, including promoters and enhancers, and frequently perturb TF recognition sequences. Thus SNPs 
associated with CVD risk may affect TF binding sites within super-enhancers in EC and other cell types 
relevant to CVD. 
 
In this study, we show that ERG regulates a subset of endothelial super-enhancers, and that CVD-
associated SNPs are enriched at ERG enhancers and super-enhancers. The association of ERG-bound loci 
with CVD risk variants provides candidate SNPs for future studies on the epigenomic pathways underlying 
cardiovascular pathologies. 
 
 
 
METHODS 
 
All supporting data are available within the article and its Online Data Supplement. Sequencing data 
generated in this study (ChIP-Seq datasets for ERG, H3K27ac and MED1 in HUVEC) have been made 
publicly available at the NCBI Gene Expression Omnibus (GEO), and can be retrieved through accession 
number GSE124893. 
 
An expanded Methods section is available in the Online Supplement. 
 
 
 
RESULTS 
 
Integrated genomic analysis reveals an ERG-regulated transcriptional program for the vascular 
endothelium. 
 
ChIP-seq analysis in HUVEC identified 40821 genomic ERG binding sites associated with 14786 
genes. Selected ERG peaks in the promoters of known ERG target genes CDH5 and ICAM1 were validated 
by ChIP-qPCR (Online Figure IA). As expected, the canonical ERG motif (C/a/g)(A/C)GGAA(G/A)23 was 
the most represented at ERG sites in HUVEC (Online Figure IB). Globally, analysis of the distribution of 
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ERG binding sites relative to annotated transcription start sites (TSS) revealed that most ERG-bound 
regions were intragenic and intergenic sites located distally from the promoter (+/- 2kb from TSS) (Figure 
1A).  
 
Integrated analysis of global expression profiling24 with ERG ChIP-seq showed that ERG binds 
85% (1232/1454) of its activated targets and 80% (939/1180) of its repressed targets (Online Figure IC). 
Gene ontology (GO) pathway analysis revealed that directly activated ERG targets clustered in functions 
related to angiogenesis, blood vessel morphogenesis and hemostasis, while repressed genes associated with 
TGFβ/SMAD signaling and stress pathways (Figure 1B), in line with its known roles.  
 
ERG-bound enhancers drive endothelial gene expression. 
 
We next examined the relationship between ERG binding and chromatin states in HUVEC using 
data from the Encyclopedia of DNA Elements (ENCODE) Consortium25. 97% of ERG peaks mapped to 
regions of DNase I hypersensitivity, a marker of accessible open chromatin26. Analysis of known ERG 
target genes showed ERG genomic loci overlapping histone marks of active promoters (H3K4me3 and 
H3K27ac) and enhancers (H3K4me1 and H3K27ac) at sites of DNase I hypersensitivity (Figure 1C and 
Online Figure ID). Globally, ERG binding in HUVEC was greatest at active enhancers (Figure 1D).  
 
ERG-bound enhancers were identified in known ERG targets, including CDH5. Four ERG-bound 
active enhancers, named E1 to E4, were selected based on H3K27ac and H3K4me1 enrichment in a 23kb 
region along the CDH5 locus either side of the TSS (Online Figure IIA). The E1, E2 and E4 enhancers, but 
not the repeat DNA-containing E3 enhancer, were individually cloned into luciferase reporter vectors 
containing the CDH5 promoter, previously characterized as transactivated by ERG27. In HeLa cells (which 
do not express endogenous ERG), all enhancers increased ERG-dependent transactivation of the CDH5 
promoter, with E4 being the most active (data not shown). This was then validated in HUVEC, where the 
E4 enhancer increased basal CDH5 promoter activity >4-fold (Figure 1E); moreover, this region was 
responsive to ERG transactivation, which further increased luciferase activity by 9-fold compared to CDH5 
promoter alone (Figure 1E). Mutation of the nine AGGAA putative ERG-binding motifs in region E4 
(Online Figure IIB, C) completely abolished enhancer activity and the response to ERG (Figure 1E).  
These findings support a key role for ERG-mediated transactivation of gene expression through EC 
enhancers. 
 
ERG binds to HUVEC super-enhancers. 
 
Multiple ERG-bound enhancers were found in close proximity with each other in ERG activated 
genes, such as CDH5 (see Figure 1C). Clusters of enhancers, known as super-enhancers can be 
distinguished from isolated typical enhancers by enrichment in lineage-specific TF, co-activators such as 
Mediator complex subunit 1 (MED1) and the histone modification mark H3K27ac18, 19, 28. Super-enhancers 
preferentially associate with genes that define cell lineage identity18, 19. To define endothelial super-
enhancers, we identified enhancer regions by co-occupancy of H3K27ac and H3K4me1 in HUVEC25. 
Enhancers within 12.5kb of each other were then concatenated to define a single entity, and ranked by 
increasing H3K27ac enrichment, as described28. The analysis identified 917 super-enhancers (Figure 2A 
and Online Table I) that mapped to 822 genes, including ERG activated targets VWF, CDH5, ICAM2, 
SOX17, DLL4, as well as ERG itself (Figure 2A, B). A similar super-enhancer profile was obtained when 
ranked by MED1 enrichment (Online Figure IIIA).  
 
Genes associated with endothelial super-enhancers were found to have significantly higher mean 
expression levels compared to those associated with typical enhancers (Figure 2C). Gene Set Enrichment 
Analysis (GSEA) showed significant enrichment of ERG driven genes with the top 500 ranked super-
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enhancer genes (Figure 2D). These data suggest that ERG regulates endothelial gene expression via super-
enhancers.  
 
Remarkably, the vast majority of super-enhancers (93%) were bound by ERG, compared to only 
34% of typical enhancers (Figure 3A). In keeping with higher TF occupancy at super-enhancers19, the 
canonical ERG motif was significantly more bound by ERG in super-enhancers compared to typical 
enhancers (35% vs 25%, respectively)  (Online Figure IIIB). Furthermore, within the 917 super-enhancers, 
H3K27ac and ERG binding signal significantly correlated (Figure 3B). We thus tested whether ERG itself 
could be used to identify super-enhancers in EC. Using ERG enrichment at active enhancers as the ranking 
parameter, we identified 1125 super-enhancers in HUVEC (Figure 3C), associated with a similar gene set 
as the H3K27ac super-enhancers (see Figure 2A). Indeed, GSEA demonstrated a strong positive correlation 
between super-enhancers defined by ERG and those by H3K27ac (Figure 3D). Moreover, functional 
clustering of H3K27ac super-enhancers  and ERG super-enhancers revealed shared pathways essential to 
EC identity and function (Figure 3E).  
 
Thus, ERG binding identifies super-enhancers in differentiated endothelial cells and supports the 
prominent role of ERG as a lineage-determining transcription factor for the vascular endothelium. 
 
Differential super-enhancers binding underlies the lineage-specific activity of ERG. 
 
At odds with its homeostatic role in EC, aberrant ERG expression due to chromosomal 
translocations, such as the TMPRSS2:ERG gene fusions in prostate cells, is a hallmark of cancer (reviewed 
in 14). To exploit ERG’s therapeutic potential in the vasculature it is crucial to understand the molecular 
basis of its lineage-specific role. Therefore, we compared ERG bound gene targets in HUVEC with those 
from VCaP prostate cancer cells carrying the TMPRSS2:ERG gene fusion. Two publicly available ERG 
ChIP-seq datasets in VCaP cells29, 30 were found to correlate highly (Online Figure IVA); we used the data 
in Chng et al.29 for further analysis. Integration of this ChIP-seq data with transcriptome profiling of ERG-
depleted VCaP cells31 identified 584 genes bound and activated by ERG and 589 genes bound and repressed 
by ERG (Online Figure IVB). GO pathway analysis showed regulation of genes involved in DNA 
replication, cell proliferation, cytoskeletal remodeling and apoptosis (Figure 4A). We next examined the 
overlap between genes directly bound by ERG in VCaP cells versus HUVEC (Online Figure IVC). 
Interestingly, only 249 ERG bound target genes (8%) were found in common between HUVEC and VCaP 
cells (Figure 4B and Online Table II); of these only 58% were activated or repressed concurrently in both 
cell types (Figure 4C). Interestingly, even pathways controlled by ERG in both HUVEC and VCaP cells 
(such as cell migration, adhesion and Notch signaling) are regulated in a lineage-specific manner (Online 
Figure IVD). Selected ERG transcriptional targets were validated in HUVEC and VCaP cells by RT-qPCR 
(Online Figure IVE). 
 
Comparison of ChIP-seq datasets between HUVEC and VCaP cells showed that only 23% of ERG 
bound sites are in common between the HUVEC and VCaP genomes (Online Figure IVF). Interestingly, 
the majority (70%) of these shared sites are located close (±1kb) to the TSS (Figure 4D). In contrast, the 
proportion of ERG binding sites unique to HUVEC or VCaP cells are preferentially located at sites distal 
to the TSS (Figure 4D). Mapping of ERG genomic binding with histone modification marks confirmed a 
significant overlap of ERG binding to promoters in HUVEC and VCaP cells (Figure 4E, left). However, no 
significant overlap was observed between ERG binding at enhancers in HUVEC and VCaP cells, with only 
18% of ERG binding sites found at enhancers in VCaP cells (Figure 4E, right). We next asked whether 
ERG binding in VCaP cells was also associated with super-enhancers. Using ranked enrichment of 
H3K27ac from ChIP-seq in VCaP cells32, we identified 208 super-enhancers (Figure 5A). Genes associated 
with super-enhancers in VCaP had significantly higher average expression levels compared to those 
associated with isolated typical enhancers (Online Figure VA), as expected. The vast majority of VCaP 
super-enhancers were bound by ERG (91%), compared to 48% of typical enhancers (Figure 5B). 
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Interestingly, GSEA showed no significant relationship between super-enhancer-associated genes in VCaP 
cells and HUVEC (Online Figure VB). GO analysis revealed different pathways regulated by super-
enhancer-associated genes in HUVEC compared to VCaP cells (Figure 5C). Finally, super-enhancers 
occupied by ERG showed cell-lineage specificity: endothelial ERG-regulated genes (such as CDH5) are 
associated with super-enhancers in HUVEC but not VCaP cells, and vice versa for VCaP cell genes (such 
as TMPRSS2) (Figure 5D and Online Figure VC).  
 
The difference between super-enhancer profiles in HUVEC versus VCaP cells suggests that the 
chromatin landscape is unique to the particular cell type. Analysis of  histone modifications associated with 
active (H3K27ac and H3K4me1) or repressed (H3K27me3) chromatin in HUVEC and VCaP super-
enhancer regions supports this hypothesis. Genomic regions corresponding to HUVEC SE were enriched 
in active histone marks in HUVEC but not VCaP (Figure 5E, top). Conversely, genomic regions 
corresponding to VCaP SE were enriched in active marks in VCaP but not HUVEC (Figure 5E, bottom). 
The reverse pattern was observed for the repressive mark H3K27me3 (Online Figure VD).  
 
To further define the lineage-specific machinery of super-enhancers, we focused on TFs that may 
collaborate with ERG to regulate gene transcription in a cell type-specific manner. We searched for TF 
DNA motifs located +/-200bp from the ERG binding sites in HUVEC and VCaP cells. Interestingly, 
different TF motifs are enriched in ERG binding sites in the two cell types. In HUVEC, these include AP-
1, FOXO1, GATA2 and SOX3, TFs known to be important in endothelial gene expression16, 33 (Figure 5F, 
top). In VCaP cells, the enriched motifs included TFs FOXA1 and HOXB13, TFs previously described to 
play a role in prostate cancer gene expression34 (Figure 5F, bottom).  
These data indicate that ERG’s lineage-specific transcriptional activity is associated with binding to cell 
type-specific super-enhancers, and suggests cooperativity with distinct lineage-specific factors. 
 
ERG controls the gene expression profile in HUVEC by regulating the enhancer and super-enhancer 
landscape. 
 
We investigated whether ERG is required for H3K27 acetylation at endothelial enhancers by 
performing H3K27ac ChIP-seq analysis in HUVEC treated with control or ERG-siRNA (Online Figure 
VIA,B). In control HUVEC, 56347 H3K27ac-bound regions were identified, which significantly correlated 
with those reported in the ENCODE data25 (Online Figure VIC). In ERG-deficient cells, H3K27ac was 
modulated globally, with a decrease in H3K27ac at 5277 regions (loss) and an increase in 1648 regions 
(gain) (Figure 6A,B). Changes in H3K27ac enrichment were validated by ChIP-qPCR across regions 
associated with selected endothelial ERG target genes (Figure 6C). Globally, in ERG-deficient cells 
changes in H3K27ac also correlated with the expression profile: expression of genes associated with loss 
of H3K27ac was significantly downregulated whilst expression of genes associated with gain of H3K27ac 
was significantly upregulated (Figure 6D and Online Figure VID). Genomic Regions Enrichment of 
Annotations Tool (GREAT) analysis of ERG-depleted HUVEC showed that loss of H3K27ac was 
associated with enrichment of Notch and VEGF receptor signaling, pathways positively controlled by 
ERG8, 35 (Figure 6E). In contrast, gain of H3K27ac was associated with TGFβ-SMAD signaling, a pathway 
repressed by ERG11 (Figure 6E).  
 
To investigate the effect of ERG depletion on the recruitment of basal transcriptional machinery to 
enhancers, we carried out ChIP-seq for MED1 in control and ERG-deficient HUVEC. Loss or gain of 
MED1 occupancy in ERG-deficient cells coincided with a decrease or increase in H3K27ac, respectively 
(Figure 6F). These data indicate that ERG plays a role in modulating endothelial enhancers. MED1 is part 
of a large complex (Mediator) which interacts with super-enhancers19. We therefore investigated the role 
of ERG in the organization of endothelial super-enhancers. H3K27ac ChIP-seq analysis in control HUVEC 
identified 1015 super-enhancer clusters (Figure 7A, siCtl), in line with the HUVEC super-enhancers profile 
identified from ENCODE data (see Figure 2A). ERG depletion by siRNA caused changes in H3K27ac 
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levels leading to a redistribution of endothelial super-enhancers (Figure 7A; siERG). Comparison of 
H3K27ac super-enhancers in control versus ERG-depleted HUVEC identified a subset of 107 super-
enhancers with decreased H3K27ac levels following loss of ERG. Amongst the ERG-regulated super-
enhancers were those associated with key endothelial genes including DLL4, NRARP and CLDN5 (Figure 
7B). The majority of super-enhancers showed no significant changes following ERG siRNA, and only a 
few super-enhancers showed increased H3K27ac. MED1 occupancy was also reduced in the subset of ERG-
regulated super-enhancers (decreased SE) compared to those unchanged (constant SE) (Figure 7C). 
Importantly, the ERG-dependent decrease in H3K27ac levels correlates with reduced expression of ERG 
target genes (Online Figure VIIA). Thus, ERG is functionally required to dynamically modulate H3K27ac 
levels in endothelial cells leading to redistribution of a subset of super-enhancers. 
 
Cooperative TF binding and p300 recruitment in the regulation of HUVEC super-enhancers  
 
ERG has been shown to bind to p300 35; thus we hypothesized that ERG-dependent changes in 
H3K27ac at super-enhancers might be linked to the recruitment of p300 by ERG. This was tested by ChIP-
qPCR for p300 enrichment on selected loci associated with validated ERG targets (CLDN5, DLL4), where 
H3K27ac was decreased upon loss of ERG (decreased SE). These showed a significant decrease in p300 
occupancy following ERG inhibition, suggesting that ERG is required to recruit p300 at these sites (Figure 
7D). However, ERG inhibition did not consistently affect p300 recruitement at constant SE typified by IL6 
and PXN (Figure 7D). Online Figure VIIB illustrates the ERG-dependent decrease in H3K27ac and MED1 
occupancy observed at the CLDN5 and DLL4 gene loci, compared to loci associated with constant SE, IL6 
and PXN. These findings suggest that ERG regulates a subset of super-enhancers partly through recruitment 
of the histone acetyltransferase p300.  
 
We speculated that in the super-enhancers that remain constant following loss of ERG, other TFs 
might compensate for its absence. Previous studies have identified GATA and AP-1 (FOS/JUN) TF families 
as cooperating with ETS factors in regulating endothelial gene expression16, 36; moreover, cJUN has been 
shown to bind p30037. Analysis of ChIP-seq data from ENCODE for GATA2, cFOS, and cJUN in 
HUVEC25 showed significant global overlap with ERG-bound sites (Online Figure VIIC). Higher 
occupancy of GATA2, cFOS and cJUN was present at constant SE compared to decreased SE (Figure 7E). 
This global distribution is reflected at representative loci for the two groups; CLDN5, DLL4 (decreased SE) 
and IL6, PXN (constant SE) (Online Figure VIIB).   
 
These data suggest a model (Figure 7F) in which the majority of SE are regulated by a cooperative 
TF network involving ERG, AP-1 and GATA2 that provide a strong transcriptional complex; thus loss of 
ERG can be compensated. However, in a subset of SE-associated lineage genes including CLDN5 and 
DLL4, AP-1 and GATA2 are less abundant, and therefore there is low cooperativity and SE assembly and 
gene expression are strongly dependent on ERG. 
 
Risk variants for cardiovascular and other diseases are enriched at ERG super-enhancers. 
 
Several studies have recently shown that disease-associated SNPs identified through GWAS are 
preferentially enriched in the super-enhancer regions of disease-relevant cells, and can map to TF binding 
sites18, 38. Endothelial dysfunction is implicated in many diseases. We examined the enrichment of disease-
associated variants at ERG binding loci, ERG-bound enhancers and ERG super-enhancers, using SNPs 
reported in the NCBI dbGaP39 and NHGRI-GWAS catalogs40. We determined enrichment by using a null 
distribution of background population variants.  Analysis at ERG binding loci identified association with 
SNPs for immune diseases and CVD (Online Figure VIIIA). At ERG-bound enhancers the significance of 
enrichment is greatly amplified, with a similar repertoire of disease traits (Online Figure VIIIB). 
Interestingly, analysis at ERG super-enhancers identified SNPs for CVD as the most highly associated 
disease trait (P = 1.1 x10-14) (Figure 8A). ERG super-enhancers were also enriched in diseases for digestive 
D
ow
nloaded from
 http://ahajournals.org by on March 25, 2019
 DOI: 10.1161/CIRCRESAHA.118.313788   9 
system (P = 5.7 x10-5) and respiratory tract (P = 6.1 x10-5) (Figure 8A). This enrichment was not identified 
at size- and chromosome-matched regions randomly shuffled (permuted) across permissive chromatin. 
Further interrogation of the CVD-associated SNPs revealed strong significant enrichment for traits such as 
abdominal aortic aneurysm (P = 1.7 x10-13), coronary artery disease (P = 2.6 x10-10), myocardial infarction 
(P = 5.1 x10-9) and hypertension (P = 1.1 x10-8), but not heart failure (Figure 8B), suggesting a closer 
association with diseases where EC contribute most to the pathogenesis. 
 
These results identify a novel mechanisms through which disease associated non-coding SNPs may 
cause vascular dysfunction and increased disease risk, and suggest a possible functional link between ERG-
dependent transcriptional regulation of endothelial gene expression and the predisposition to CVD.  
 
 
 
DISCUSSION 
 
In this study, we characterize the transcription factor ERG as a crucial regulator of enhancers and 
super-enhancers in HUVEC. Multiple studies have shown that ERG is essential to maintain endothelial 
homeostasis (reviewed in 2). Here we define the ERG-dependent endothelial epigenome and associate this 
with genetic variants linked to CVD and other diseases, suggesting novel potential strategies for biomarkers 
and target identification.  
 
Our study identifies ERG as a positive regulator of a core set of putative endothelial super-
enhancers in HUVEC. We describe an ERG-dependent subset of super-enhancers, associated with essential 
endothelial genes such as DLL4, CLDN5 and NRARP. Crucially, ERG-dependent super-enhancers are 
significantly associated with ERG-activated genes. Analysis of DLL4 and CLDN5 loci shows that 
recruitment of p300 at these super-enhancer is controlled by ERG; direct interaction between ERG and 
p300 35 suggests a mechanism by which ERG recruits p300 to genomic loci for H3K27 acetylation. 
However, inhibition of ERG expression in HUVEC did not perturb activity in most super-enhancer regions. 
This is not surprising since super-enhancers are characterized by the presence of multiple TF binding sites 
and a high degree of enrichment of transcriptional co-activators, providing opportunities for cooperative 
binding and synergistic gene activation18, 19. Transcriptional networks consisting of members of the ETS 
(including ERG’s closest homologue FLI1), AP-1 and GATA families have been shown to bind endothelial 
enhancers16, 41. Furthermore, ERG and AP-1 have been shown to functionally interact at composite DNA 
binding sites in non-EC42. As suggested from studies on AP-1 43, endothelial enhancer selection may be 
facilitated by cooperative ERG-AP-1 binding where ERG is acting as the endothelial-specific transcription 
factor. A recent study investigated the effect of combined knockdown of ERG and its closest homologue 
FLI1 on global H3K27ac levels in HUVEC and found a significant loss of H3K27ac on key endothelial 
genes41, supporting the notion that multiple TFs are directing cooperative transcriptional regulation. In our 
study, we found that the majority of endothelial super-enhancers are co-occupied by ERG, AP-1 members 
cFOS/cJUN, and GATA2. Interestingly, we found that the subset of super-enhancers not affected by ERG 
depletion is highly co-occupied by ERG, AP-1 and GATA2, whilst lower levels of all TF are present at the 
subset sensitive to ERG depletion. We propose that a cooperative TF network is able to compensate for 
ERG depletion at most super-enhancers; however, a specific subset of core super-enhancers is strictly 
dependent on ERG function, highlighting its key role in regulating endothelial gene expression.  
 
ERG may modulate super-enhancer activity through mechanisms other than p300 recruitment. A 
potential mechanism may be through targeting the activity of the BAF (BRG1-associated factors) chromatin 
remodeling complex which disrupt histone-DNA interactions to control access to DNA44. Recent studies 
have indicated a role for both AP-1 and ERG in binding to BAF subunits to establish accessible chromatin 
for enhancer selection and target gene regulation43, 45. The mechanism through which ERG modulates 
MED1 recruitment remains unclear. Mediator complex has been implicated in long-range chromatin 
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interactions functionally combining enhancers from many kilobases away. In fact, super-enhancers have 
been shown to form higher-order 3D chromatin structures which are likely to coordinate their activity in an 
orchestrated manner38, 46. In this study, we followed the current standard convention when annotating super-
enhancer-associated regions with ERG-bound loci, namely by their linear distance along the epigenome28. 
This methodology does not take into account the complex 3D chromatin structure. Further studies will be 
required to map super-enhancers using long-range chromatin interactions in the HUVEC genome. 
Aberrant expression of lineage-specific TF in other tissues cause deregulated activation of a 
transcriptome profile detrimental to the cell15; this is indeed the case with ERG, which acts as an oncogene 
when overexpressed in cells such as the prostate epithelium13. We show that ERG-associated super-
enhancer profiles are markedly different in HUVEC compared to VCaP cells. Thus, ERG does not co-opt 
an endothelial genomic profile in VCaP cells but controls fundamentally different pathways in these two 
cell types, partly through selective super-enhancer binding. These findings provide some insight into the 
molecular basis for ERG’s homeostatic versus oncogenic functions. We postulate that different ERG-
dependent gene expression between HUVEC and VCaP cells may be regulated in part by the activity of 
cell-specific pioneer factors which act to prime chromatin for accessibility at at lineage-specific sites47.  
 
Super-enhancer regions are commonly enriched in cell type-specific disease-related SNPs18, 38. 
Hogan et al.16 identified disease trait-associated SNPs for CAD and hypertension within aortic endothelial 
enhancers. Our analysis of ERG-bound super-enhancers revealed enrichment for SNPs associated with 
diseases that have a vascular component, including predisposition to cardiovascular diseases, such as 
atherosclerosis and CAD. These data supports the notion that active maintenance of endothelial homeostasis 
through transcriptional programs is essential protection against a number of diseases, most of all CVD. 
Interestingly, recent GWAS meta-analysis revealed a novel risk locus for abdominal aortic aneurysm within 
the ERG gene itself48. Further studies will determine the functional role of non-coding variants associated 
with ERG enhancers, and will provide crucial insight into the contribution of ERG, cooperative TF and co-
factor binding in complex disease susceptibility.  
 
In conclusion, this study provides novel evidence on the transcriptional and epigenetic mechanisms 
which controls lineage-specific gene expression in EC and identifies a possible functional link between 
regulation of ERG activity and human disease. These associations will provide valuable insights for 
investigating the role of ERG-dependent regulatory programs in maintaining endothelial homeostasis and 
protecting against vascular diseases. 
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FIGURE LEGENDS 
 
Figure 1. Characterization of ERG-bound enhancers in HUVEC. (A) Percentage genomic distribution 
of ERG ChIP-seq peaks. (B) Gene ontology analysis showing pathways associated with differentially 
regulated ERG-bound endothelial target genes (genes activated in blue, genes repressed in red). 
Significance shown as -log(p-value). (C) ChIP-seq binding profiles for ERG, H3K4me1, H3K27ac, 
H3K4me3 and DNase I hypersensitivity in HUVEC; loci of ERG-activated CDH5 (top) and ERG-repressed 
ICAM1 (bottom). The x-axis represents the genomic position; the y-axis the ChIP-seq signal in reads per 
million per base pair (rpm/bp). ERG binding sites are shown as black bars. (D) Number of ERG binding 
sites associated with specific epigenomic features versus size-matched random regions. Active enhancers 
are defined by combined H3K4me1 and H3K27ac, poised enhancers by H3K4me1 and H3K27me3, and 
active promoters by H3K4me3 and H3K27ac. (E) Luciferase reporter plasmids (pGL4) containing the 
CDH5 promoter with or without region E4 or a mutant enhancer (E4mut), were co-transfected into HUVEC 
along with an ERG cDNA expression plasmid (pcDNA-ERG) or empty vector control, pcDNA3.1. Values 
are represented as the fold change in relative luciferase activity over the empty vector alone. Values are 
mean ± SEM, n = 3. A two-way ANOVA showed significance (P<0.001) and a post hoc test using Tukey 
multiple comparisons test shows pairwise differences between specific groups, ***P<0.001. 
 
Figure 2. Characterization of HUVEC super-enhancers identifies enrichment for ERG and ERG-
target genes. (A) HUVEC enhancer regions identified by H3K27ac and H3K4me1 were ranked by 
enrichment of H3K27ac ChIP-seq signal in rpm/bp. Super-enhancer (SE) clusters are shown to the right of 
the gray dashed line. (See also Online Table V) (B) HUVEC SE regions indicated as red bars above density 
plots of ERG ChIP-seq signal alongside H3K27ac at distal enhancers of VWF, ICAM2, and ERG loci. (C) 
Transcriptome profiling of HUVEC shows significantly higher gene expression in SE than in typical 
enhancers. ***P< 0.0001, Wilcoxon rank-sum test. (D) GSEA of the top 500 SE-associated genes compared 
with the ranked gene list from transcriptome profiling of ERG-deficient HUVEC. Normalised enrichment 
score (NES) = 2.13, P < 0.001.  
 
Figure 3. ERG defines SE in HUVEC. (A) ERG binding at SE and typical enhancer regions. SE have 
significantly more ERG bound than typical enhancers; ***P<0.0001, Fisher’s exact test. (B) Scatterplot of 
the correlation between ERG and H3K27ac occupancy (log2 transformed) in the 917 SE regions. Each point 
is the mean ChIP-seq signal across each SE region; P<0.001. (C) SE ranked by ERG enrichment on 
identified enhancer regions. Known ERG-target genes proximal to SE are indicated. (See also Online Table 
VI) (D) GSEA of the top 500 genes associated with ERG-identified SE compared with the ranked gene list 
from 917 H3K27ac-enriched SE. NES = 1.54, P < 0.001. (E) Gene ontology analysis was carried out on 
the genes associated with SE identified by enrichment for H3K27ac or ERG. The top 7 biological processes 
ranked by significance (–log(p-value)) are depicted. 
 
Figure 4. ChIP-seq analysis identifies a lineage-specific program for ERG: ERG expression and 
binding profile in prostate cancer cells. (A) Gene ontology pathway analysis of differentially regulated 
ERG-bound target genes in VCaP prostate cancer cells (activated genes in blue, repressed genes in red). 
Significance of pathway enrichment as -log(p-value). (B) Venn diagram comparing ERG bound, 
differentially regulated genes in HUVEC and VCaP cells. Only 249 genes (in bold) are common to the two 
cell types. None of the fractions overlap significantly between the 2-way comparisons using a 
hypergeometric distribution test. (C) Heatmap of expression levels of the shared 249 bound and regulated 
putative ERG target genes following ERG inhibition in HUVEC and in VCaP cells. (D) Genomic view of 
percentage distribution of ERG peaks relative to TSS in regions bound by ERG that are shared between 
HUVEC and VCaP cells, HUVEC only or VCaP cells only. (E) Overlap of ERG binding sites at H3K4me3-
enriched and RefSeq assigned TSS promoter regions (left), and H3K27ac/H3K4me1-enriched enhancers 
(right), in HUVEC and VCaP cells. Significance reported by a hypergeometric test p-value. 
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Figure 5. ERG associates with lineage-specific super-enhancers. (A) Identification of VCaP SE by 
H3K27ac ChIP-Seq signal in rpm/bp. (See also Online Table VII) (B) ERG binding at SE and typical 
enhancers in VCaP cells. SE have significantly more ERG binding than typical enhancers; ***P<0.0001, 
Fisher’s exact test. (C) Gene ontology analysis on the SE-associated genes in HUVEC (red) and VCaP cells 
(blue). The top 5 biological processes in both cells are ranked by significance (–log(p-value)). (D) ChIP-
seq binding profiles for ERG and H3K27ac occupancy in HUVEC (left) and VCaP cells (right). H3K27ac-
defined SE regions are depicted as blue bars below tracks. (E) Aggregate plots of active histone 
modifications H3K27ac and H3K4me1 histone modifications from HUVEC and VCaP cells in HUVEC SE 
(top panels) and VCaP SE (bottom panels). Plots centered on the SE center. The average size of VCaP SE 
are smaller than those identified in HUVEC. (F) Motif analysis at ERG binding sites (±200bp) in HUVEC 
and VCaP. Top 5 most enriched transcription factor families are shown with the most highly occurring 
member of each family represented. Motifs for the binding of critical lineage transcription factors coincide 
with the ERG motif in both HUVEC and VCaP cells. 
 
Figure 6. ERG contributes to enhancer activation in HUVEC. (A) Volcano plot showing log2 fold 
change (FC) vs –log(p-value) of differential H3K27ac enrichment at siCtl H3K27ac regions in response to 
ERG knockdown. Loss and gain enhancer regions are selected by -1  log2FC  1; -log(p-value)  4. (B) 
Heatmap of H3K27ac enrichment over input in all loss and gain regions. Signal ±5 kb from the centre of 
H3K27ac siCtl or siERG regions as tag density/bp. (C) ChIP-qPCR of H3K27ac at enhancers of CLDN5, 
DLL4 and VWF with a negative control gene desert, in siCtl vs siERG treated HUVEC. Graph represents 
fold change over IgG, n=3. *P < 0.05, paired two-tailed t-test. (D) Boxplot representing log2FC from 
transcriptome profiling data following ERG knockdown in H3K27ac regions changed in response to siERG 
(as defined in A). P < 0.0001, Kruskal-Wallis test and post-hoc test using Wilcoxon rank-sum test ****P < 
0.0001; *P < 0.05. (E) Pathway analysis of genes associated with loss and gain of H3K27ac. (F) Boxplot 
showing the log2FC of MED1 occupancy in siERG-treated HUVEC in H3K27ac regions changed in 
response to siERG. P < 0.0001, Kruskal-Wallis test and post-hoc test using Wilcoxon rank-sum test, ****P 
< 0.0001.  
 
Figure 7. ERG regulates distinct endothelial super-enhancers. (A) SE identification on siCtl H3K27ac 
using H3K27ac enrichment from siCtl and siERG-treated HUVEC. Selected genes relevant to endothelial 
function are indicated in red. (See also Online Table VIII) (B) Volcano plot depicting the log2FC vs –log(p-
value) of differential super-enhancers at 1015 H3K27ac SE identified in siCtl treated cells. Significantly up 
or downregulated super-enhancers are selected according to -0.58  log2FC  0.58 (-1.5  FC  1.5); -log(p-
value)  4. (C) Boxplot representing the log2FC of MED1 occupancy in siERG-treated HUVEC in 
decreased SE and constant SE. ****P < 0.0001, Wilcoxon rank-sum test. (D) ChIP-qPCR of p300 
enrichment in siCtl or siERG-treated HUVEC at selected SE constituent enhancers (E) associated with 
decreased SE (CLDN5, DLL4) or constant SE (IL6, PXN). Data are represented as fold change over IgG, 
n=4. *P < 0.05, paired two-tailed t-test. (E) Genomic occupancy of ERG and collaborative TFs: GATA2, 
cFOS and cJUN at decreased SE compared to constant SE, measured by the ChIP-seq signal in HUVEC. 
****P < 0.0001; ***P < 0.001; *P<0.05, Wilcoxon rank-sum test. (F) Model of ERG-dependent SE 
assembly in EC. Cooperative SE activation is associated with a strong transcriptional complex (ERG, AP-
1, GATA2) at constant SE (left). In a subset of SE, activation of SE is strongly dependent on ERG due to 
less abundance of transcription factor network partners with reduced cooperativity. 
 
Figure 8. ERG super-enhancers prioritize cardiovascular disease variants. (A) Overlap of GWAS 
SNPs associated with disease trait classes within ERG defined SE (orange) with chromosome and size 
matched random SE (gray). Significance of enrichment was calculated by binomial distribution test with 
red dashed line indicating P = 0.05. Some points overlay. (B) Test for enrichment of selected CVD trait-
associated SNPs within ERG defined SE (orange) with chromosome and size matched random SE (gray), 
as performed in A. Random region were restricted to open chromatin by excluding placement in repressed 
chromatin states in HUVEC. 
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NOVELTY AND SIGNIFICANCE  
 
What Is Known? 
 
 The ETS transcription factor ERG is essential for endothelial homeostasis, whereas its aberrant 
over-expression in cancer is oncogenic. 
 
 Lineage-specific transcription factors bind to chromatin regulatory elements, called super-
enhancers, which are enriched in single nucleotide polymorphisms (SNPs) associated with specific 
diseases, including CVD. 
 
 
 Epigenomic mechanisms are emerging as key players in cardiovascular disease (CVD); little is 
known about the epigenetic regulation of endothelial function and its links to CVD. 
 
What New Information Does This Article Contribute? 
 
 The transcription factor ERG drives endothelial lineage genes via super-enhancers. 
 
 Comparison of human umbilical vein endothelial cells (HUVEC) and prostate cancer. 
 
 TMPRSS2:ERG fusion-positive VCaP cells reveals distinctive lineage-specific transcriptome and 
super-enhancer profiles. 
 
 ERG regulates a core set of endothelial super-enhancers that have reduced transcription factor 
cooperativity. 
 
 CVD-associated SNPs are enriched at ERG super-enhancers. 
 
There is an emerging link between the transcriptional and epigenetic regulation of endothelial gene 
expression and CVD. Most disease-associated SNPs lie within noncoding regions of the genome and 
perturb transcription factor recognition sequences. A key question is whether disruption of transcription 
factor pathways which promote endothelial cell homeostasis modulates disease risk. This is suggested by 
the presence of SNPs in endothelial cell enhancers linked to CVD. In this study, we focus on the 
transcription factor ERG which is required for endothelial lineage specification, vascular development and 
angiogenesis, and plays an essential role in maintaining vascular homeostasis. Profiling global ERG DNA 
binding reveals that ERG binds to and regulates endothelial super-enhancers. This is lineage-specific since 
oncogenic ERG in prostate cancer VCaP cells binds different super-enhancers compared to HUVEC. ERG 
binding at endothelial super-enhancers is associated with CVD-associated SNPs, suggesting that 
perturbation of ERG DNA-binding motifs in super-enhancers may modulate disease risk. In summary, we 
identify a novel mechanism through which the ERG transcription factor promotes endothelial cell 
homeostasis via regulation of super-enhancers. Binding of ERG to super-enhancers may have functional 
consequences for CVD risk. These findings may open new avenues of research focussing on the epigenomic 
mechanisms underlying CVD pathologies. 
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